About Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
https://www.bruker.comBruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels.
CEO
Frank H. Laukien
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Devices
Sector Healthcare
Went public September 8, 2025
Full time employees 11,396
ETFs Holding This Stock
Summary
Total 17
Showing Top 3 of 17
Ratings Snapshot
Rating : C-
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $60.75 B
52w High $419.83
52w Low $250.00
Dividend Yield 1.14%
Frequency Irregular
P/E 0
Volume 8.52K
Outstanding Shares 151.70M
About Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
https://www.bruker.comBruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $860.5M ▲ | $319.3M ▼ | $-59.6M ▼ | -6.93% ▼ | $-0.41 ▼ | $3.1M ▼ |
| Q2-2025 | $797.4M ▼ | $346M ▼ | $7.6M ▼ | 0.95% ▼ | $0.05 ▼ | $72.3M ▼ |
| Q1-2025 | $801.4M ▼ | $359.4M ▼ | $17.4M ▲ | 2.17% ▲ | $0.11 ▲ | $88.6M ▼ |
| Q4-2024 | $979.6M ▲ | $421.2M ▲ | $13.7M ▼ | 1.4% ▼ | $0.09 ▼ | $124.6M ▲ |
| Q3-2024 | $864.4M | $350.7M | $40.9M | 4.73% | $0.27 | $117.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $295M ▲ | $6.43B ▲ | $3.94B ▼ | $2.43B ▲ |
| Q2-2025 | $92M ▼ | $6.34B ▲ | $4.47B ▲ | $1.8B ▼ |
| Q1-2025 | $184.2M ▲ | $5.93B ▲ | $4.08B ▲ | $1.82B ▲ |
| Q4-2024 | $183.4M ▲ | $5.81B ▼ | $3.99B ▼ | $1.78B ▼ |
| Q3-2024 | $148.1M | $6.11B | $4.27B | $1.81B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-58.5M ▼ | $-33.2M ▲ | $-23.8M ▲ | $258.4M ▲ | $201.1M ▲ | $-54.1M ▲ |
| Q2-2025 | $4.2M ▼ | $-127.5M ▼ | $-91.1M ▼ | $95.5M ▲ | $-91.5M ▼ | $-148.8M ▼ |
| Q1-2025 | $16.8M ▲ | $65M ▼ | $-26.1M ▲ | $-51.2M ▲ | $1M ▼ | $39M ▼ |
| Q4-2024 | $13.9M ▼ | $190M ▲ | $-60.6M ▲ | $-75M ▼ | $35M ▲ | $153.3M ▲ |
| Q3-2024 | $40.3M | $38.4M | $-67.6M | $-2.7M | $-21.5M | $5.8M |
CEO
Frank H. Laukien
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Devices
Sector Healthcare
Went public September 8, 2025
Full time employees 11,396
ETFs Holding This Stock
Summary
Total 17
Showing Top 3 of 17
Ratings Snapshot
Rating : C-
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0